Trial intelligence / Profile preview

2LHERP for recurrent orofacial herpes

2024-514358-56-00Phase 4Authorised

Sponsor: Labo'Life
Start: Jun 2024
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
Countries: 1

Overview

Phase 4, randomised, double-blind trial in herpes simplex (HSV) and herpes labialis comparing 2LHERP with Placebo (2 arms). Primary endpoint: Change in annual number of herpes episodes. Planned start Jun 2024; status: authorised.

Drugs

2LHERP

Conditions

herpes simplex (HSV)herpes labialis

Beyond the preview

Go deeper on 2024-514358-56-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514358-56-00.